New combo shows promise against tough lymphoma
NCT ID NCT03113500
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new combination treatment for a rare type of lymphoma (CD30-positive peripheral T-cell lymphoma). It combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal is to see if this approach improves the number of patients who achieve complete remission. The study enrolled 48 adults and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin plus chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for CD30-positive peripheral T-cell lymphoma, potentially leading to higher remission rates.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 48 participants. Results may not apply to all patients, and side effects from the chemotherapy and targeted drug could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Promising combo tackles rare blood cancer in chinese patients
- New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
- New drug cocktail aims to tackle rare blood cancer